Partners win €1m Eurostars grant

Published: 25-Sep-2012
Research & Development Pharmaceutical

ExpreS2ion, Mucosis and Copenhagen University to develop placental malaria vaccine


Biotech companies ExpreS2ion Biotechnologies and Mucosis, with the University of Copenhagen have been awarded a Eurostars grant with of more than €1m for the pre-clinical development of a placental malaria vaccine.

The funding will be used to apply novel vaccine technologies developed at Dutch firm Mucosis and ExpreS2ion, based in Horsholm, Denmark to a malaria antigen developed at the University of Copenhagen in a project funded by The Danish National Advanced Technology Foundation. The aim of the project is to provide women in high-risk areas, such as during pregnancy, with lifelong protection against malaria.

Thomas Johnston, ceo of Mucosis, said the collaboration would combine the strengths of the firm’s Mimopath mucosal vaccine platform with the contributions of its partners.

ExpreS2ion has developed a complete proprietary protein expression platform, called ExpreS2, based on engineered Drosophila Schneider-2 (S2) cells, to serve recombinant protein production needs of research teams and recombinant sub-unit vaccine developers.

Charlotte Dyring, ceo of ExpreS2ion, added: ‘This collaboration will allow us to apply glycosylation engineering to the ExpreS2 platform, thus widening the potential of this efficient platform for production of recombinant proteins.’

  • Companies:
  • Mucosis
  • Expres2ion Biotechnologies
See more

You may also like

Ingredients

CRT and University of Copenhagen announce agreement with ADC Therapeutics to develop antibody treatments for cancer

Read more
The antibodies target an overexpressed protein on the surface of some cancer cells, which is not expressed on healthy cells

Trending Articles

  1. Roche acquires clinical-stage biopharmaceutical company Poseida Therapeutics Through the merger, Roche will acquire Poseida's allogeneic CAR-T cell therapy portfolio, including pre-clinical and clinical-stage iterations for a range of conditions
  2. Aurobindo Pharma signs $25m respiratory drug development and commercialisation deal with global pharma company The companies will co-develop and commercialise respiratory therapeutics, diversifying Aurobindo's current portfolio
  3. Merck's Welireg approved for cancers associated with von Hippel-Lindau disease in China The once-daily drug is the first HIF-2α to be approved in China, exhibiting a 49% objective response rate (ORR)
  4. Steritas and argenx join forces to advance steroid-sparing therapeutic development With the help of Steritas' STOX Suite, argenx aims to develop antibody-based therapeutics for immune diseases, potentially allowing patients to move away from chronic steroid usage

Upcoming event

CPhI Middle East

10–12 December 2024 | Conference | Riyadh, Saudi Arabia See all

You may also like

Ingredients

CRT and University of Copenhagen announce agreement with ADC Therapeutics to develop antibody treatments for cancer

The antibodies target an overexpressed protein on the surface of some cancer cells, which is not expressed on healthy cells
Research & Development

Wellcome Trust grants Mucosis €3.7m for clinical trials in partnership with Imperial College

To progress SynGEM intranasal respiratory syncytial virus (RSV) vaccine
Research & Development

Mucosis enter partnership with Changchun BCHT Biotechnology of China

Raises €5m in new financing round
Research & Development

Innovative medication to shatter blood clots with IR light

Danish professor joins five-year EU project
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Hybrid interferons: developing a novel drug class

With many hurdles to overcome, establishing a new drug candidate is a long process — particularly if you are a smaller biotech company with limited resources. These challenges can be further amplified if the candidate being developed is of an entirely novel drug class
Packaging

How pharma packaging manufacturers role is evolving: the case of extractables testing

As the pharmaceutical industry continues to grow and evolve, extractables testing is a critical component of the pharmaceutical industry's efforts to prioritise quality and safety, ensuring one of the key functions pharma containers are designed for, says Anna Malori, Head of Product Management at Bormioli Pharma
Distribution

2BScientific expands its life science product supply service to Europe with new German facility

The facility in Munich will serve the European market with life science products, including in vitro diagnostic (IVD) reagents, buffers, biomaterials and antibodies
Subscribe now